The food and drug ministry of South Korea has said that the country has approved US pharmaceutical company Pfizer Inc's (NYSE:PFE) COVID-19 vaccine for use with children aged five to 11 years, Reuters news agency reported on Wednesday.
In a statement, the ministry said that children should get one-third of the regular dose, twice with a three week interval.
Children with significantly declined immunity can get a booster four weeks later, the statement added.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses